# Redmile Growth Investments
Redmile Growth Investments is the name used for Redmile Growth Investments I, L.P., a Delaware limited partnership venture capital fund based in San Francisco and managed by the healthcare investment firm Redmile Group, LLC; it reported USD 122,000,000 sold in a private offering that began in July 2021.[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt)
| Fact | Detail |
|---|---|
| Legal name | Redmile Growth Investments I, L.P., a Delaware pooled investment fund classified as a venture capital fund[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt) |
| General partner | Redmile Growth Investments I (GP), LLC[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt) |
| Manager | Redmile Group, LLC, formed March 2007, Jeremy Green managing member and principal owner[2](https://9at.com/Adviser/801-67747) |
| Headquarters | One Letterman Drive, Suite D3-300, San Francisco, CA 94129[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt) |
| Amount sold | USD 122,000,000 against an indefinite offering amount, first sale 2021-07-14, 3 investors[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt) |
| Sector | U.S. and non-U.S. healthcare companies[2](https://9at.com/Adviser/801-67747) |
| Status (September 2026) | Manager actively filing through March 2026[3](https://www.sec.gov/Archives/edgar/data/1723888/000172388826000001/0001723888-26-000001.txt) |
## Structure and relation to Redmile Group
The Form D filed on 2021-07-28 describes Redmile Growth Investments I, L.P. as a pooled investment fund classified as a venture capital fund, offered under Section 3(c)(7) of the Investment Company Act.[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt) Its general partner is Redmile Growth Investments I (GP), LLC, and its management company is Redmile Group, LLC; both entities are listed at One Letterman Drive, Suite D3-300, San Francisco.[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt)
The Growth fund is a small vehicle inside a much larger manager. Redmile Group, LLC is a registered investment adviser (registration 801-67747, 13F file number 028-12776) whose core business is public-market healthcare investing.[4](https://www.sec.gov/Archives/edgar/data/1425738/000110465926016433/0001104659-26-016433.txt) The Growth fund sits alongside the firm's other private funds rather than standing apart from them: the Redmile fund family evidenced in SEC filings includes Redmile Private Investments I and II, Redmile Biopharma Investments III, and Redmile Strategic Fund, LP.[5](https://www.sec.gov/Archives/edgar/data/1838746/000182050521000002/xslFormDX01/primary_doc.xml) • [6](https://www.sec.gov/Archives/edgar/data/1425738/000110465921127160/0001104659-21-127160-index.html) • [7](https://www.sec.gov/Archives/edgar/data/1577105/000157710513000001/xslFormDX01/primary_doc.xml)
## Founding context and people
Redmile Group, LLC was formed in March 2007 and became operational shortly thereafter; [Jeremy Green](https://www.edgepedia.org/jeremy-green) is its managing member and principal owner, according to the firm's Form ADV brochure data.[2](https://9at.com/Adviser/801-67747) The Growth fund's Form D names three executive officers of the management company: Jeremy Green, [Mike Lee](https://www.edgepedia.org/mike-lee-investor), and [Amrit Nagpal](https://www.edgepedia.org/amrit-nagpal), all of Redmile Group, LLC. Rachel Chang, General Counsel of the management company, signed the filing.[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt) The same three individuals appear as related persons on the Form D of Redmile Biopharma Investments III, L.P., c/o Redmile Group, LLC at the same San Francisco address, indicating a shared team across the fund family.[5](https://www.sec.gov/Archives/edgar/data/1838746/000182050521000002/xslFormDX01/primary_doc.xml)
## The fund by the numbers
The Form D reports USD 122,000,000 sold against an indefinite total offering amount, with the first sale on 2021-07-14.[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt) The filing lists a minimum investment accepted from any outside investor of USD 5,000,000 and exactly 3 investors, none of them non-accredited; the investors are not named.[1](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt)
Scale context from the manager's adviser disclosures shows the Growth fund is minor within Redmile: as of 03/31/2026, Redmile Group advised 18 hedge funds with gross asset value of $3,045,085,020 and 8 venture capital funds with GAV $1,188,946,146.[2](https://9at.com/Adviser/801-67747) These figures come from the firm's brochure data as republished by a third-party aggregator and should be read as secondary to the SEC's own records.
## Strategy and the wider Redmile platform
According to its adviser disclosures, Redmile Group focuses primarily on making investments in U.S. and non-U.S. healthcare companies.[2](https://9at.com/Adviser/801-67747) The public-market side is essentially all biotech: the Q4 2025 13F filed on 2026-02-17 lists positions including 8,253,316 shares of AbSci Corporation and 15,666,731 shares of ADC Therapeutics SA, among roughly thirty life-sciences holdings.[4](https://www.sec.gov/Archives/edgar/data/1425738/000110465926016433/0001104659-26-016433.txt) The private side crosses into activism-style positions: in October 2021, Redmile Group, LLC and Redmile Private Investments II, L.P. filed a Schedule 13D on Science 37 Holdings, Inc.[6](https://www.sec.gov/Archives/edgar/data/1425738/000110465921127160/0001104659-21-127160-index.html) An earlier private vehicle, Redmile Private Investments I, L.P., filed a Form D for a $150,000,000 offering, none sold at that filing date.[7](https://www.sec.gov/Archives/edgar/data/1577105/000157710513000001/xslFormDX01/primary_doc.xml)
## Recent developments
Redmile Group remained active as a filer through 2026. It filed the Q4 2025 13F in February 2026,[4](https://www.sec.gov/Archives/edgar/data/1425738/000110465926016433/0001104659-26-016433.txt) and Redmile Strategic Fund, LP filed a Form D amendment on 2026-03-06 under Rule 506(b) and Section 3(c)(7) from the same One Letterman Drive address.[3](https://www.sec.gov/Archives/edgar/data/1723888/000172388826000001/0001723888-26-000001.txt) The adviser was SEC-registered and approved as of 04/19/2007 and still reported active fund complexes as of 03/31/2026.[2](https://9at.com/Adviser/801-67747)
## References
1. [SEC Form D — Redmile Growth Investments I, L.P. (filed 2021-07-28)](https://www.sec.gov/Archives/edgar/data/1875473/0001874233-21-000014.txt)
2. [9AT: Redmile Group — Form ADV brochure summary](https://9at.com/Adviser/801-67747)
3. [SEC Form D/A — Redmile Strategic Fund, LP (filed 2026-03-06)](https://www.sec.gov/Archives/edgar/data/1723888/000172388826000001/0001723888-26-000001.txt)
4. [SEC 13F-HR — Redmile Group, LLC, period 2025-12-31 (filed 2026-02-17)](https://www.sec.gov/Archives/edgar/data/1425738/000110465926016433/0001104659-26-016433.txt)
5. [SEC Form D — Redmile Biopharma Investments III, L.P.](https://www.sec.gov/Archives/edgar/data/1838746/000182050521000002/xslFormDX01/primary_doc.xml)
6. [SEC SC 13D — Redmile Group, LLC / Redmile Private Investments II, L.P. re Science 37 Holdings (filed 2021-10-18)](https://www.sec.gov/Archives/edgar/data/1425738/000110465921127160/0001104659-21-127160-index.html)
7. [SEC Form D — Redmile Private Investments I, L.P.](https://www.sec.gov/Archives/edgar/data/1577105/000157710513000001/xslFormDX01/primary_doc.xml)
---
*Topic: Encyclopedia › Society and history › Economics and business › Finance › Venture capital and private equity › Venture capital firms of the Americas › Healthcare and life sciences investors › Biopharma and biotech investors*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license